Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticancer embryo antigen antibody as well as preparation method and application thereof

An antibody and amino acid technology, applied in the biological field, can solve the problems of low survival rate and no particularly effective treatment for patients

Active Publication Date: 2020-01-21
HUADAO SHANGHAI BIOPHARMA CO LTD
View PDF5 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Digestive system tumors mainly include esophageal cancer, gastric cancer, liver cancer, colorectal cancer, pancreatic cancer, bile duct cancer, etc. At present, the most effective method is still surgery, and there is almost no particularly effective treatment method for those patients who lack surgical indications. Said that the 5-year survival rate is still very low, so there is an urgent need to develop new treatments for these tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer embryo antigen antibody as well as preparation method and application thereof
  • Anticancer embryo antigen antibody as well as preparation method and application thereof
  • Anticancer embryo antigen antibody as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Panning and ELISA preliminary screening of natural human phage antibody library

[0085] Panning of phage antibody library

[0086] Prepare 3 EP tubes for magnetic bead blocking and wall blocking (A: 1ml PBS, 2% Blotting-GradeBlocker, 50μl streptavidin magnetic beads, 100μl phage library; B: 1ml PBS, 2%Blotting-GradeBlocker, 100 μl streptavidin magnetic beads; C: 1 ml PBS, 2% Blotting-Grade Blocker) at room temperature for 1-2 h. Discard the solution in tube C and the magnetic beads in tube A, collect the phage in tube A and add them to tube C, and at the same time add biotin-labeled antigen CEA (final concentration 20 μg / ml), incubate at room temperature for 2 h. Collect the magnetic beads in tube B and discard the solution, add the mixture in tube C and incubate on a rotary shaker for 15 minutes. Put the EP tube on the magnetic stand and let it stand for 30s, so that the magnetic beads are adsorbed to the tube wall. Discard the supernatant, and add MPBST (PBS+2%Blo...

Embodiment 2

[0094] FACS screening of candidate clones

[0095] Cell culture was performed according to standard cell culture protocols, and single-cell suspensions were prepared by trypsinizing the cells. Centrifuge (300g, 5min) to remove the culture medium and resuspend the cells to 2*10 6 cell / ml. Add 2*10 to each well of the round bottom 96-well plate 5 cell suspension of cells. After centrifugation at 300 g for 5 min, the supernatant was removed, and the cells were resuspended with 100 μl of periplasmic protein extract, and incubated at 4°C for 1 h. After centrifugation at 300g for 5min, the supernatant was removed, the cells were resuspended in Flow solution, and repeated 3 times to remove periplasmic protein extracts. Dilute anti-myc antibody to 2 μg / ml with blocking solution, resuspend cells in 100 μl per well, and incubate at 4°C for 1 hour. After washing the cells with Flow Buffer for 3 times, add 100 μl of Alexa-488 anti-mouse antibody to resuspend the cells, and incubate a...

Embodiment 3

[0103] Off-rate ranking candidate clones

[0104] Antibody affinity depends on the degree of fit between the variable region of the antibody and the antigen, and is generally assessed by affinity. The dissociation constant (Koff) is generally the main kinetic mechanism affecting antibody affinity, so by measuring the dissociation rate, the level of antibody affinity can be initially compared. At the same time, Koff is concentration-independent, so Koff can be measured without purification of antibodies. Determining the Koff of candidate clones by Octet Red and sorting will help to further select clones for subsequent analysis. Bacterial periplasmic extracts were prepared according to standard operating procedures. The biotin-labeled antigen (5 μg / ml) was immobilized on the streptavidin SA biosensor, the periplasmic extract was diluted 2-fold with 1×kinetic buffer, the binding time of antigen and scFv antibody was 300s, and the dissociation time was 300s. SA biosensors were ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an anti-CEA (carcinoembrynio antigen) antibody which comprises a heavy chain variable region and a light chain variable region, wherein the complementary determining region of the heavy chain variable region comprises CDR (complementary determining region)-H1 of which the amino acid sequences are shown in SEQ ID NO.1 in the description, CDR-H2 of which the amino acid sequences are shown in SEQ ID NO.2 in the description and CDR-H3 of which the amino acid sequences are shown in SEQ ID NO.3 in the description; and the complementary determining region of the light chain variable region comprises CDR-L1 of which the amino acid sequences are shown in SEQ ID NO.4 in the description, CDR-L2 of which the amino acid sequences are shown in SEQ ID NO.5 in the description and CDR-L3 of which the amino acid sequences are shown in SEQ ID NO.6 in the description. The inventor of the invention screens CEA scFv by using a phage display technology, and thus obtains a high-affinityanti-CEA single-chain antibody. In addition, an anti-CEA chimeric antigen receptor gene is introduced into T cells by using a genetic engineering method to prepare CEA CAR-T, so that CEA CAR-T cellsare capable of specifically recognizing and killing digestive tract tumor cells expressing CEA, and thus the anti-tumor effects of the CEA CAR-T cells can be achieved.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to an anti-carcinoembryonic antigen antibody and its preparation method and application. Background technique [0002] The concept of Chimeric antigen receptor T cells (CAR-T) has appeared as early as 1989, but it has not achieved the desired effect in clinical trials. In the following two decades, scientists continued to try and optimize this, until 2011, CD19 (B lymphocyte antigen CD19, CD19) targeted CAR-T cells were used in relapsed / refractory chronic B lymphocytic leukemia Clinical research, and achieved amazing curative effect. So far, the application of CAR-T cells in tumor treatment has opened a new chapter. [0003] Chimeric antigen receptors are artificially synthesized fusion proteins that function similarly to T cell receptors, mainly including signal peptides, antigen recognition regions, hinge regions, transmembrane regions, and intracellular signal regions. After bindi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/30C07K19/00C12N15/13C12N5/10G01N33/574A61K39/395A61K39/00A61P35/00
CPCA61K2039/505A61P35/00A61K39/001129C07K14/7051C07K16/3007C07K2317/622C07K2317/92C07K2319/02C07K2319/03C07K2319/33C12N5/0636C12N5/0646C12N2510/00G01N33/57473G01N33/57484
Inventor 狄升蒙井洋洋陈鑫冯冬歌余学军
Owner HUADAO SHANGHAI BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com